Sodium-Glucose Cotransporter 2 Inhibitors for People with Type 1 Diabetes.

Kim,  Choong Hee; Moon,  Jun Sung

doi:2019.20.2.92

J Korean Diabetes > Volume 20(2); 2019 > Article

Focused Issue

The Journal of Korean Diabetes 2019;20(2):92-98.
DOI: https://doi.org/10.4093/jkd.2019.20.2.92 Published online July 17, 2019.

제1형 당뇨병 환자에서 Sodium-Glucose Cotransporter 2 억제제 사용

김중희, 문준성

Sodium-Glucose Cotransporter 2 Inhibitors for People with Type 1 Diabetes.

Choong Hee Kim, Jun Sung Moon

Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea. mjs7912@yu.ac.kr

Abstract

Althowgh intensive insulin regimen is the main treatment in people with type 1 diabetes, glucose variability and weight gain remain as challenges for this treatment. Sodium-glucose cotransporter (SGLT) inhibitors (including the SGLT1/2 inhibitors) have emerged as an add-on therapy for insulin treatment in peoples with type 1 diabetes due to their insulin-independent mechanism. Recent clinical trials have consistently reported that SGLT inhibition provides additive benefits in glycemic control, including lower insulin dose and weight loss. However, there is concern that an increase in ketone-related adverse events such as diabetic ketoacidosis is higher in SGLT1/2, as well as SGLT2 inhibitors. Despite safety issues that require further evaluation, SGLT2 inhibitors used with caution may provide an adjunctive therapy in people with type 1 diabetes.

Key Words: Diabetes mellitus, type 1, Diabetic ketoacidosis, Insulin, Sodium-glucose cotransporter-2 inhibitor